Skip to content
ppharmaranks
Menu
Class IIOngoing

Levoxyl (levothyroxine sodium tablets recall

FDA recall D-0052-2027 · initiated Sep 29, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Oct 28, 2026How we research

Pfizer recalled Levoxyl (levothyroxine sodium tablets in Sep 2026 — an FDA Class II recall (D-0052-2027) because Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot # 24W06, Exp: 11/30/2026

Quantity recalled: 15,815 100-count bottles

Details

Product
Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01.
Recalling company
Pfizer Inc
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
US Nationwide and Puerto Rico
Initiated
Sep 29, 2026
FDA report date
Oct 28, 2026

This recall is linked to a product we cover: Levoxyl →

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Levoxyl (levothyroxine sodium tablets recalled?
Pfizer recalled Levoxyl (levothyroxine sodium tablets in Sep 2026 — an FDA Class II recall (D-0052-2027) because Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Levoxyl (levothyroxine sodium tablets recalled?
Per the FDA enforcement record, the reason for recall D-0052-2027 was: Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
Is a recalled Levoxyl (levothyroxine sodium tablets dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Levoxyl (levothyroxine sodium tablets are affected?
Distributed: US Nationwide and Puerto Rico. The recall covers these lots — Lot # 24W06, Exp: 11/30/2026. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0052-2027.

Source: openFDA Drug Enforcement record D-0052-2027 ↗

← All drug recalls